Related Experiment Video
Updated: Aug 15, 2026
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
Published on: November 8, 2011
Significance of the blood beryllium lymphocyte proliferation test
1Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206, USA. newmanl@njc.org
Insights
The blood beryllium lymphocyte proliferation test (BeLPT) identifies beryllium sensitization and chronic beryllium disease (CBD) earlier and more accurately than other tests. This vital tool aids in early diagnosis, prognosis, and understanding occupational lung disease development.
Area of Science:
- Immunology
- Occupational Health
- Pulmonology
Background:
- Chronic beryllium disease (CBD) pathogenesis involves beryllium antigen-specific cell-mediated immune response.
- The blood beryllium lymphocyte proliferation test (BeLPT) measures this immune response in vitro.
- Despite methodological considerations, the BeLPT shows significant clinical utility.
Purpose of the Study:
- To evaluate the effectiveness of the blood BeLPT in diagnosing beryllium sensitization and CBD.
- To assess the BeLPT's role in clinical decision-making and disease management.
- To explore the BeLPT's application in screening exposed worker populations.
Main Methods:
- In vitro measurement of beryllium antigen-specific lymphocyte proliferation.
- Clinical assessment and diagnosis of chronic beryllium disease.
- Field assessment and application in worker populations.
Main Results:
- The BeLPT identifies beryllium sensitization and CBD earlier and more effectively than existing clinical tests.
- Diagnosed CBD cases are clinically significant, with potential for progression requiring treatment.
- The BeLPT improves diagnostic accuracy and corrects misdiagnoses.
- The test demonstrates high sensitivity, specificity, and predictive value for CBD screening in exposed workers.
- The BeLPT has identified previously missed cases of beryllium sensitization and CBD in occupational settings.
Conclusions:
- The BeLPT is a crucial tool for early detection and diagnosis of beryllium-related lung conditions.
- It aids in managing patients with CBD and predicting disease progression.
- The BeLPT is valuable for screening exposed populations and advancing research into occupational lung diseases.
Abstract:
The blood beryllium lymphocyte proliferation test (BeLPT) is an in vitro measure of the beryllium antigen-specific cell-mediated immune response. This response to beryllium is now understood to play a central role in the immunopathogenesis of chronic beryllium disease (CBD). Although there remain some unresolved methodologic issues with testing, the blood BeLPT has already undergone sufficient development and field assessment to lead to a number of important conclusions: a) The BeLPT identifies beryllium sensitization and CBD earlier and better than any other clinical test presently available. b) The CBD cases identified with the blood test are clinically significant. c) A subset of the people identified by the BeLPT who do not yet have clinical disease will progress and require treatment with corticosteroids for impairing illness. d) The BeLPT can be used to improve clinical diagnostic accuracy and to correct mistaken diagnoses. e) The blood test can be used in screening large numbers of exposed workers because it is sensitive and specific and has high positive and negative predictive value for CBD. f) In every workforce studied to date, the BeLPT has identified beryllium sensitization and CBD that had been missed by conventional screening efforts. g) Worker populations that have been characterized using the BeLPT can help to elucidate the role of exposure genetics and dysregulated inflammation in the genesis of occupational lung disease.
